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A hexanucleotide (GGGGCC) expansion in C9ORF72 gene is the most common genetic change seen in familial
Frontotemporal Lobar Degeneration (FTLD) and familial Motor Neurone Disease (MND). Pathologically, expansion
bearers show characteristic p62 positive, TDP-43 negative inclusion bodies within cerebellar and hippocampal
neurons which also contain dipeptide repeat proteins (DPR) formed from sense and antisense RAN (repeat associated
non ATG-initiated) translation of the expanded repeat region itself. ‘Inappropriate’ formation, and aggregation, of DPR
might therefore confer neurotoxicity and influence clinical phenotype. Consequently, we compared the topographic
brain distribution of DPR in 8 patients with Frontotemporal dementia (FTD), 6 with FTD +MND and 7 with MND alone
(all 21 patients bearing expansions in C9ORF72) using a polyclonal antibody to poly-GA, and related this to the extent
of TDP-43 pathology in key regions of cerebral cortex and hippocampus. There were no significant differences in either
the pattern or severity of brain distribution of DPR between FTD, FTD +MND and MND groups, nor was there any
relationship between the distribution of DPR and TDP-43 pathologies in expansion bearers. Likewise, there were no
significant differences in the extent of TDP-43 pathology between FTLD patients bearing an expansion in C9ORF72
and non-bearers of the expansion. There were no association between the extent of DPR pathology and TMEM106B
or APOE genotypes. However, there was a negative correlation between the extent of DPR pathology and age at
onset. Present findings therefore suggest that although the presence and topographic distribution of DPR may be
of diagnostic relevance in patients bearing expansion in C9ORF72 this has no bearing on the determination of clinical
phenotype. Because TDP-43 pathologies are similar in bearers and non-bearers of the expansion, the expansion may
act as a major genetic risk factor for FTLD and MND by rendering the brain highly vulnerable to those very same factors
which generate FTLD and MND in sporadic disease.
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Frontotemporal Lobar Degeneration (FTLD) is a clinical,
pathological and genetically heterogeneous condition.
The major clinical syndromes principally involve person-
ality and behavioural change (behavioural variant fronto-
temporal dementia, or bvFTD) or language alterations of
a fluent (semantic dementia) or non-fluent (progressive
non-fluent aphasia) nature [1]. All three syndromes can
be accompanied by Motor Neurone Disease (MND)
though the combination of FTD and MND is most com-
mon [1]. Causative mutations have been identified in tau
(MAPT) [2], progranulin (GRN) [3,4], CHMP2B [5], and
most recently in C9ORF72 [6-8]. This latter genetic change
is characterized by an expansion of a hexanucleotide
(GGGGCC) repeat region in the first intron or the pro-
moter region of C9ORF72 gene, occurring in patients with
either FTLD or MND, or a combination of both [6-8], and
can number in excess of as many as 1500 repeats [9]. The
expansion is found in about one in every twelve patients
with FTLD and 1 in 10 patients with MND.
Pathologically, most FTLD cases with the expansion
[6,8,10-13], like many non-mutational cases of FTLD
[14,15], show inclusion bodies within neurones (NCI)
and glial cells of the cerebral cortex and hippocampus
that contain the nuclear transcription factor, TDP-43.
However, they also show a unique pathology within the
hippocampus [10,16,17] and cerebellum [10-12,16,17]
characterised by NCI that are TDP-43 negative, but
immunoreactive to p62 protein. At least some of the
target protein(s) within these p62-positive NCI are
dipeptide repeat proteins (DPR) [17-20] formed from
sense and antisense RAN (repeat associated non ATG-
initiated) translation of the expanded repeat region itself
[18-23]. ‘Inappropriate’ formation, and aggregation, of
DPR may therefore confer neurotoxicity and influence
clinical phenotype.
Previous studies on DPR in FTLD and MND have
been largely limited to investigations on the hippocam-
pus and cerebellum [17,18], though one previous study
[24] performed a wider topographic screen for DPR on
35 expansion cases with FTLD (n = 9) or MND (n = 8),
or FTLD with MND (n = 18). This study failed to detect
any significant differences in regional distribution or
severity of DPR between each clinical group. In the
present study, we too have determined how widely DPR
are distributed throughout the brain in patients with
FTLD and others with MND, and what cell types are af-
fected, comparing the topographic distribution of DPR
in patients with FTLD and MND in order to assess to
what extent this distribution relates to the clinical ex-
pression of each disorder, and how it might relate to the
underlying TDP-43 proteinopathy. Furthermore, because
TMEM106B genotype has been claimed to be a genetic
modifier of FTLD [25-29], and to protect C9ORF72carriers from FTD [25,28,29], we investigated whether
this might influence both the distribution and severity of
both DPR and TDP-43 pathologies in FTLD cases. We
also performed a similar analysis in respect of Apolipo-
protein E (APOE) genotype since there have many studies
claiming an increased frequency of APOE ε4 allele in
FTLD (see [30-33] for examples) and this might operate
by facilitating pathological changes, as it does in Alzhei-
mer’s disease where possession of APOE ε4 allele is asso-
ciated with increased deposition of amyloid β protein
[34] and cerebral amyloid angiopathy [35].
Materials and methods
Patients
Sixty seven patients were investigated in total. Fourteen
patients with FTLD (cases#1-14, 9 males, 5 females), and
7 with MND (cases#41-47, 6 males, 1 female) bore ex-
pansions in C9ORF72 (as evidenced by Southern blot
and/or repeat primed PCR) (see Table 1 and Additional
file 1: Table S1). We also investigated a further 14 other
patients with FTLD (cases#27-40, 11 males, 3 females),
and 20 other patients with MND (cases#48-67, 12 males,
8 females), all with no known mutation, and 12 patients
with FTLD bearing a mutation in GRN (cases#15-26, 7
males, 5 females) (see Table 1 and Additional file 1:
Table S1). All genetic analyses have been reported by
us elsewhere [2,3,13,36,37]. Tissues from 39/40 FTLD
and 23/27 of the MND cases were obtained from the
Manchester Brain Bank through appropriate consenting
procedures for the collection and use of the human brain
tissues. All cases were from the North West of England
and North Wales. The other FTLD case (case#14) and the
further 4 MND cases (cases#44-47) were obtained from
Institute of Psychiatry Brain Bank (London). Again, these
were obtained through appropriate consenting procedures
for the collection and use of the human brain tissues. The
40 patients with FTLD fulfilled Lund-Manchester clinical
diagnostic criteria for FTLD [38,39] and were consistent
with recent consensus criteria [40,41]. The 27 patients
with MND fulfilled El Escorial criteria [42].
From clinical and neuropsychological assessments, 8
of the 14 FTLD cases with an expansion in C9ORF72
had a pure/predominant bvFTD phenotype, whereas the
other 6 showed a mixed bvFTD and MND phenotype.
Five of the FTLD patients without known mutation
showed bvFTD phenotype, 3 had a progressive non-
fluent aphasia (PNFA) phenotype and 6 showed a mixed
bvFTD and MND phenotype. Pathologically, among the
C9ORF72 expansion bearers with FTLD, all 8 patients
with bvFTD had FTLD-TDP type A histology, whereas
all 6 patients with FTD +MND had FTLD-TDP type B
histology (according to Mackenzie et al. 2011 [43]). Of
the 14 FTLD patients with no known mutation, 4 had
FTLD-TDP type A histology (2 with bvFTD phenotype
Table 1 Mean (±SD) age at onset, death and duration of illness for groups of patients with FTD, FTD +MND or MND
associated with expansions in C9ORF72, or mutations in GRN, or not known to be associated with any known FTLD or
MND associated genes
Group M/F Age at onset (y) Age at Death (y) Duration of illness (y)
C9ORF72 FTD 7/1 61.1 ± 8.5 67.6 ± 7.0 6.5 ± 3.0
C9ORF72 FTD +MND 2/4 58.8 ± 6.1 64.7 ± 5.8 5.8 ± 6.2
C9ORF72 MND 6/1 55.8 ± 8.6 57.6 ± 7.6 2.8 ± 1.7
All C9ORF72 cases 15/6 58.9 ± 7.8 63.4 ± 7.9 5.2 ± 4.1
GRN FTD 7/5 60.8 ± 5.9 69.7 ± 3.9 8.8 ± 3.8
Non-mutational FTD 2/2 60.8 ± 11.9 68.0 ± 15.6 7.3 ± 4.1
Non-mutational FTD + MND 9/1 59.3 ± 7.0 65.4 ± 8.2 6.2 ± 3.8
All non-mutational FTD 11/3 59.6 ± 12.7 63.4 ± 13.6 2.4 ± 1.1
Non-mutational MND 12/8 59.7 ± 8.2 66.1 ± 10.2 6.5 ± 3.8
FTD = Frontotemporal Dementia, FTD +MND + Frontotemporal dementia and Motor Neurone disease, MND =Motor Neurone Disease.
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ology (3 with bvFTD phenotype, 1 with PNFA pheno-
type and 6 with FTD +MND phenotype). All 12 patients
bearing GRN mutation displayed FTLD-TDP type A
histology; 6 had bvFTD phenotype and 6 had PNFA
phenotype. All 27 patients with MND displayed charac-
teristic TDP-43 pathology in mid brain and brainstem
motor nerve nuclei, and in spinal cord (where this was
available for study). These were usually skein-like in ap-
pearance, but occasionally more rounded, solid-appearing
inclusions were also present.
Histological methods
Paraffin sections were cut (at a thickness of 6 μm) from
formalin fixed blocks of representative regions of brain
to include (where available) frontal cortex (BA8/9), tem-
poral cortex (BA21/22), cingulate gyrus, insular cortex,
motor cortex, inferior parietal and occipital (BA17/18)
cortex. Blocks were also cut from the amygdala and pos-
terior hippocampus, basal ganglia (to include caudate
nucleus, putamen, globus pallidus and thalamus), sub-
stantia nigra (to include oculomotor nucleus), pons (to
include locus caeruleus and V cranial nerve nucleus),
medulla (to include inferior olives and XII cranial nerve
nucleus), cerebellum (with dentate nucleus) and cervical
and lumbar spinal cord (where available).
Sections from each brain region were immunostained
with a poly-GA antibody (courtesy of M Hasegawa), as
described previously [44]. The antibody was used at dilu-
tion of 1:1000–1:3000. This antibody was raised against
poly-(GA)8 peptide with cysteine at N-terminus, con-
jugated to m-maleimidobenzoyl-N-hydrosuccinimide
ester-activated thyroglobulin. The thyroglobulin-peptide
complex (200 μg) emulsified in Freund’s complete adjuvant
was injected subcutaneously into a New Zealand White
rabbit, followed by 4 weekly injections of peptide complex
emulsified in Freund’s incomplete adjuvant, starting after2 weeks after the first immunization. Immunoreactivity of
the antisera was characterized by ELISA as follows. The
peptide immunogens were coated onto microtiter plates.
The plates were blocked with 10% fetal bovine serum
(FBS) in PBS, incubated with the rabbit antisera di-
luted in 10% FBS/ PBS at room temperature for 1.5 h,
followed by incubation with HRP-goat anti-rabbit IgG
(Bio-Rad) at 1:3000 dilution, and reacted with the sub-
strate, 0.4 mg/mL o-phenylenediamine, in citrate phos-
phate buffer (24 mM citric acid, 51 mM Na2HPO4).
The absorbance at 490 nm was measured using Plate
Chameleon (HIDEX). In addition, sections of temporal
cortex with hippocampus from 11 (non-expansion bearing)
cases with other histological and genetic forms of FTLD,
other neurodegenerative disorders and healthy controls
(see Table 1) were also immunostained for DRP with anti
poly-GA antibody as ‘negative controls’. Antibodies were
employed in standard IHC protocol, though antigen
unmasking was performed by pressure cooking in citrate
buffer (pH 6, 10 mM) for 30 minutes, reaching 120 degrees
Celsius and >15 kPa pressure.
Further sections of frontal cortex and temporal cortex
with hippocampus were immunostained for both phos-
phorylated (at Ser 409/410), and non-phosphorylated,
TDP-43 (rabbit polyclonal antibodies (pS409/410-2 anti-
body, Cosmo Biotech Ltd, Tokyo, Japan and 10782-2-AP
antibody, Proteintech, Manchester, UK, respectively – at
1:3000 and 1:1000, respectively).
Pathological assessment
The presence of DPR immunostained NCI within nerve
cells was assessed at ×20 magnification in those brain re-
gions where all cases could be represented, according to:
0 = no DPR immunostained NCI present in any field.
0.5 = rare/single DPR immunostained NCI present in
entire section.
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but not all fields.
2 = a moderate number of DPR immunostained NCI
present in each field.
3 = many DPR immunostained NCI present affecting
many cells in each field.
4 = very many DPR immunostained NCI present,
affecting nearly all cells in every field.
Scores per assessed area were summated across those
regions where these were available for all 21 individuals
with C9ORF72 expansions. Brain regions were grouped
on an anatomical or a ‘functional’ basis. Hence, scores
from frontal, temporal, cingulate, insular, parietal and
occipital cortical regions were summated to generate a
total ‘cortical’ score for each case. Scores from hippo-
campus and adjacent regions of subiculum, entorhinal
cortex and fusiform gyrus were summated to give a total
medial temporal lobe score for each case. Scores for
caudate nucleus, putamen, globus pallidus, thalamus,
substantia nigra, locus caeruleus and dorsal raphe were
summated to give a total ‘subcortical’ score. Scores in
motor cortex and in X and XII cranial nerve nuclei were
summated to give a total ‘motor’ score. Scores in cere-
bellar granule and Purkinje cells, and in cells of the den-
tate nucleus, inferior olives and pontine nuclei were
summated to give a total ‘cerebellar’ score. Due to the
unavailability of tissue in all cases, it was not possible to
include scores for amygdala (absent from 5/21 cases) or
spinal cord (absent from 10/21 cases) within the medial
temporal lobe or motor region analyses, respectively.
The frequency of TDP-43 pathological changes (as
NCI and neurites, where present) in each of frontal and
temporal cortex (pyramidal cells of layers II) and hippo-
campus (dentate gyrus granule cells), was scored semi-
quantitatively according to:
0 = no TDP-43 immunostained NCI and/or neurites.
0.5 = rare/single TDP-43 immunostained NCI and/or
neurite present in entire section.
1 = very few TDP-43 immunostained NCI and/or
neurites.
2 = a moderate number of TDP-43 immunostained NCI
and/or neurites.
3 = many TDP-43 immunostained NCI and/or neurites,
affecting many cells in every field.
4 = very many immunostained NCI and/or neurites
present, affecting nearly all cells in every field.
TDP-43 pathology cores per assessed area were sum-
mated across those regions where these were available
for all individuals. Hence, scores from dentate gyrus of
hippocampus, and from frontal and temporal cortex,
were summated (in all except 4 cases where dentategyrus was not available) to give a total TDP-43 pathology
score for each case.
Genetic analysis
DNA was extracted from blood or frozen brain tissue by
routine phenol-chloroform extraction. The TMEM106B
assay was genotyped by allelic discrimination using the
Applied Biosystems pre-developed assay cat number
C_7604953_10. Genotyping was carried out using the
Applied Biosystems 7900, and genotypes were assigned
automatically using the SDS 2.3 software. APOE was ge-
notyped according to Wenham [45].
Statistical analysis
Rating data was entered into an excel spreadsheet and
analyzed using Statistical Package for Social Sciences
(SPSS) software (version 17.0). Kruskal-Wallis or Mann–
Whitney test was used to compare inclusion scores be-
tween several groups or pairs of groups, respectively. All
correlations were performed using Spearman rank cor-
relation test. In all instances, a p-value of less than 0.05
was considered statistically significant.
Results
Demographics
Mean ages at onset, death and duration of illness for
C9ORF72 associated FTD, FTD+MND and MND groups,
FTD associated with GRN mutation, non-mutational FTD,
FTD +MND and MND groups are shown in Table 1.
ANOVA comparison of age at onset, death and dur-
ation of illness between all 7 diagnostic groups revealed
no significant differences in age at onset (F6,51 = 0.27,
p = 0.946) or death (F6,56 = 1.4, p = 0.227), though dur-
ation of illness differed between the groups (F6,51 = 4.3,
p = 0.001). As would be expected, post-hoc analysis
showed that duration of illness was significantly less in
C9ORF72 cases with MND than C9ORF72 associated
FTD (p = 0.014), but not less than C9ORF72 associated
FTD +MND (p = 0.281), nor was there any difference
in disease duration between C9ORF72 associated FTD
and C9ORF72 associated FTD+MND (p = 0.815). Again,
as expected, non-mutational MND showed a shorter dur-
ation of illness than non-mutational FTD (p = 0.022) and
non-mutational FTD +MND (p = 0.013). However, there
were no significant differences in duration of illness be-
tween C9ORF72 associated FTD, non-mutational FTD or
GRN associated FTD (F2,37 = 1.6, p = 0.215), or between
C9ORF72 associated FTD+MND and non-mutational
FTD +MND (p = 0.900), or between C9ORF72 associated
MND and non-mutational MND (p = 0.605).
ANOVA comparison of age at onset, death and duration
of illness between C9ORF72 associated FTD, FTD+MND
and MND groups alone revealed no significant group dif-





Figure 1 Topographic brain distribution of dipeptide repeat
proteins (poly-GA) in patient #9 with Frontotemporal dementia
associated with an expansion in C9ORF72. Regions shown are
frontal cortex layer II (a), frontal cortex layer V (b), dentate gyrus
(c) and area CA4 (d) of hippocampus, ventrolateral nucleus of
thalamus (e), granule cells (f) and Purkinje cells (g) of cerebellum,
dentate nucleus (h). Immunoperoxidase-haematoxylin ×40
microscope magnification.
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ness tended to differ between the 3 groups (F2,18 = 4.1,
p = 0.045).
Cytological observations
All cases had been previously classified on the basis of
the type and distribution of TDP-43 immunoreactive
changes according to Mackenzie et al. 2011 [43], and
hence showed TDP-43 histological changes typical of
the group in which they had been placed. These have
been well described previously, both by ourselves and
others, and are therefore not further detailed in the
present study.
DPR were characteristically present in all FTLD and
MND cases previously known to bear expansions in
C9ORF72, but none were seen in any of the cases bear-
ing GRN mutations, nor in any of the other FTLD cases
or MND cases not known to be associated with any
FTLD or MND linked mutation.
In cases of FTD and FTD +MND, DPR were observed
to be most frequent within the cerebral neocortex,
hippocampus and cerebellum. They were infrequent or
absent in basal ganglia regions, and were rare or usually
absent in mid brain, brainstem, medulla and spinal cord
regions. DPR were present in neuronal cytoplasmic
inclusions (NCI) throughout all cortical layers in all
regions of the cerebral cortex examined. In outer cor-
tical layers they were mostly present in small non-
pyramidal neurons appearing as dots or clusters of
granules (Figure 1a), whereas in the deeper cortical layers
DPR were again present in smaller non-pyramidal neurons
as clusters of granules, but in the larger pyramidal cells
they often adopted a more star-shaped or spicular appear-
ance (Figure 1b). Granular type DPR were particular nu-
merous in parietal and occipital cortex and in motor
cortical regions in most cases, and common in frontal and
temporal cortex when these areas were not severely
degenerated, though in cases where these regions were
badly degenerated DPR were much less frequent.
In the hippocampus, DPR were present as abundant,
small, rounded NCI within granule cells of the dentate
gyrus (Figure 1c), though more spicular or granular in-
clusions were commonly seen within pyramidal cells
of areas CA4 and CA2/3 (Figure 1d), becoming less
frequent in CA1 region and subiculum. Again neurons
containing small clusters of DPR were present through-
out all layers of the entorhinal cortex. Small granular or
spicular NCI were widespread within the amygdala,
though usually only to a moderate extent, and less se-
verely than in the hippocampus.
Generally, DPR were sparse within basal ganglia re-
gions. They were occasionally present as spicular NCI in
small neurons in the caudate nucleus and putamen, and
in larger neurons of the globus pallidus but were morecommon in the thalamus, especially those of the ventro-
lateral nuclei (Figure 1e). DPR were rarely (if ever) seen
in cells of the substantia nigra, locus caeruleus, nucleus
basalis of Meynert, dorsal raphe nucleus, basalis pontis,
in motor nuclei of III, IV, V, X or XII cranial nerves, or
in anterior horn cells of the spinal cord (where available
for study). However, in a few cases DPR were occa-
sionally seen as spicular NCI in neurons of the inferior
olives.
In the cerebellum, DPR were widespread within gran-
ule cells of the cerebellum (Figure 1f ). As with the cere-
bral cortex, more granular looking NCI were usually
present in basket cells, with occasional spicular NCI
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the dentate nucleus (Figure 1h), but none were seen
within Golgi neurones, or within Bergmann glia. A
punctate, or filamentous, staining was also seen within
the molecular layer of the cerebellum, this probably relat-
ing to parallel projection fibres (Figure 1g). A similar dis-
tribution of DPR was observed in the 7 MND cases
bearing expansions in C9ORF72 to that seen in the FTD
and FTD +MND cases (Figure 2).
Comparisons of DPR ratings
Composite rating scores for DPR pathology are shown
for each case in Table 2. When Comparisons of rating
scores for DPR, showed no significant differences in
total severity scores for DPR between FTD, FTD +MND
and MND cases for cortical (χ2 = 0.19, p = 0.911), hippo-
campal (χ2 = 3.7, p = 0.160), motor (χ2 = 2.3, p = 0.323),
subcortical (χ2 = 2.56, p = 0.279) or cerebellar (χ2 = 2.3,
p = 0.318) regions, or for total score summated across all
5 subregions (χ2 = 1.4, p = 0.487) (Table 2). Similarly,
when analysed by region, there were no significant differ-
ences in DPR scores between any of the cortical regions
investigated, either over all cases, or according to clinical
subgroups.
When all cases were grouped, there were significant
correlations between the severity of DPR pathology and
age at onset of disease for cortical (rs = −0.620, p = 0.004),Figure 2 Topographic brain distribution of dipeptide repeat proteins
with an expansion in C9ORF72. Regions shown are frontal cortex layer II
hippocampus, ventrolateral nucleus of thalamus (e), granule cells (f) and P
Immunoperoxidase-haematoxylin ×40 microscope magnification.hippocampal (rs = −0.537, p = 0.015), motor (rs = −0.482,
p = 0.031) and for total score summated across all 5 sub-
regions (rs = −0.583, p = 0.016), but not for subcortical
(rs = −0.218, p = 0.356) or cerebellar (rs = −0.137, p = 0.318)
regions. However, there was no significant correlation
between the severity of DPR pathology and duration
of disease, except weakly so in cerebellum (rs = −0.493,
p = 0.027).
Comparisons of DPR severity scores according to pos-
session of at least one copy of APOE ε4 allele were per-
formed on 12/14 FTLD cases and 3/7 MND cases (for
whom DNA was available for genotyping). No significant
differences in DPR severity scores were found between ε4
allele bearers and non-bearers, either overall (p = 0.240) or
according to subregion (cortical (p = 0.130), hippocampal
(p = 0.189), motor (p = 0.887), subcortical (p = 0.506) or
cerebellar (p = 0.640).
Due to availability of DNA, TMEM106B genotypes
were only available for 7 of the 14 FTLD cases, and 1 of
the 7 MND cases, bearing C9ORF72 expansions, 9 of
the 12 GRN mutation carriers, and 10 of the 14 FTLD
cases and 1 of the 20 MND cases without known muta-
tion. Because TMEM106B SNPs rs1020004, rs1990622
and rs6966915 were in complete linkage disequilibrium,
pathological analyses were confined to rs 1990622. Un-
fortunately, only one of the FTLD, and none of the
MND cases, irrespective of type or presence of mutation,(poly-GA) in patient #23 with Motor Neurone Disease associated
(a), frontal cortex layer V (b), dentate gyrus (c) and area CA4 (d) of
urkinje cells (g) of cerebellum, dentate nucleus (h) and putamen (i).
Table 2 Summated scores for DPR pathology ratings in Cortical, Medial Temporal, Motor, Subcortical and Cerebellar
regions, as well as total score across all 5 regions, for patients with FTD (cases #1-8), FTD +MND (cases#9-14) and MND
(cases#41-47) associated with expansion in C9ORF72
Case ID# Summated DPR score
Pathology Cortex Medial temporal Motor Subcortical Cerebellar Total
1 FTLD-TDP A 16 12 3 3 5 39
2 FTLD-TDP A 12 14 3 1 5.5 35.5
3 FTLD-TDP A 15 18 3 5 7.5 48.5
4 FTLD-TDP A 13 12 2 2.5 3.5 33
5 FTLD-TDP A 12 11 1 3 3 30
6 FTLD-TDP A 11 9 1.5 3 2 26.5
7 FTLD-TDP A 12 9.5 1 5.5 3.5 31.5
8 FTLD-TDP A 22 23 2 4 5.5 55.5
9 FTLD-TDP B 20 15.5 2 1 4.5 43
10 FTLD-TDP B 12 11 2 2 4 31
11 FTLD-TDP B 11 10.5 2 1.5 4 29
12 FTLD-TDP B 18 16 3.5 4.5 5 47
13 FTLD-TDP B 11 11 2 3.5 2 29.5
14 FTLD-TDP B 16 15 3 4.5 6.5 45
41 MND 16 13 3 6 5.5 43.5
42 MND 15 13 3 3 1 35
43 MND 14 18 3 4 3 42
44 MND 12 18 2.5 5 3 40.5
45 MND 13 12 3 1.5 4.5 34
46 MND 11 19 2 4.5 3 39.5
47 MND 23 23 3 5 3.5 57.5
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C9ORF72 expansion bearers, 4 of the FTLD cases were
homozygotes for the major allele and 3 were heterozy-
gotes, with the MND case being homozygous for the
major allele. Of the GRN mutation bearers, 5 of the
FTLD cases were homozygotes for the major allele and
4 were heterozygotes. Of the non-mutational FTLD cases,
6 were homozygotes for the major allele, 2 were heterozy-
gotes and 1 was homozygous for the minor allele.
Nonetheless, comparisons of DPR severity scores were
performed between FTLD cases heterozygous (TC) and
homozygous (TT) for the major allele. No significant dif-
ferences in DPR severity scores were found between
bearers of TC or TT genotypes, either overall (p = 0.881)
or according to subregion (cortical (p = 0.881), hippocam-
pal (p = 0.549), motor (p = 0.495), subcortical (p = 0.546) or
cerebellar (p = 0.878).
Comparisons of TDP-43 ratings
Composite rating scores for TDP-43 pathology are shown
for each case in Table 3. There were no significant differ-
ences in the severity of TDP-43 pathology scores betweenFTLD cases bearing expansions in C9ORF72, FTLD cases
without expansions, and FTLD cases with GRN mutation
for either frontal cortex (χ2 = 1.95, p = 0.377), temporal cor-
tex (χ2 = 1.94, p = 0.379) or dentate gyrus of hippocampus
(χ2 = 1.55, p = 0.461), or as total TDP-43 severity score
(χ2 = 1.82, p = 0.403). Moreover, there were no signifi-
cant differences in the severity of TDP-43 pathology
scores between FTLD cases with type A histology bearing
an expansion in C9ORF72, FTLD cases with type A hist-
ology but without expansion in C9ORF72 mutation, and
FTLD cases with GRN mutation and type A histology for
either frontal cortex (χ2 = 2.27, p = 0.321), temporal cor-
tex (χ2 = 0.66, p = 0.719) or dentate gyrus of hippocampus
(χ2 = 5.45, p = 0.065), or as total TDP-43 severity score
(χ2 = 2.19, p = 0.334). Similarly, there were no significant
differences in the severity of TDP-43 pathology scores
between FTLD cases with type B histology bearing an ex-
pansion in C9ORF72 and FTLD cases with type B hist-
ology but without expansion in C9ORF72 mutation for
either frontal cortex (p = 0.570), temporal cortex (p = 0.147)
or dentate gyrus of hippocampus (p = 0.344), or as total
TDP-43 severity score (p = 0.254).
Table 3 Summated scores for TDP-43 pathology ratings
in Frontal and Temporal cortex, and Dentate Gyrus, as
well as total score across all 3 regions, for patients with
FTD (cases #1-8) or FTD +MND (cases#9-13) associated
with C9ORF72 expansions, and for patients with FTLD
due to GRN mutation (case#15-26) or not associated with
any known mutation (cases#27-40)
Case ID# Gene Pathology TDP-43 score
DG TCX FCX Total
1 C9ORF72 FTLD-TDP A 1 4 3 8
2 C9ORF72 FTLD-TDP A 2 4 3 8
3 C9ORF72 FTLD-TDP A 2 1 3 6
4 C9ORF72 FTLD-TDP A 1 3 3 7
5 C9ORF72 FTLD-TDP A 1 1 1 3
6 C9ORF72 FTLD-TDP A 2 2 2 6
7 C9ORF72 FTLD-TDP A 1 1 2 4
8 C9ORF72 FTLD-TDP A 2 2 3 7
9 C9ORF72 FTLD-TDP B 3 2 2 7
10 C9ORF72 FTLD-TDP B 4 4 4 12
11 C9ORF72 FTLD-TDP B 4 3 3 10
12 C9ORF72 FTLD-TDP B 1 2 2 5
13 C9ORF72 FTLD-TDP B na 3 3 na
15 GRN FTLD-TDP A na 4 4 na
16 GRN FTLD-TDP A na 2 2 na
17 GRN FTLD-TDP A 4 3 3 10
18 GRN FTLD-TDP A 2 2 2 6
19 GRN FTLD-TDP A 3 3 3 9
20 GRN FTLD-TDP A 1 4 4 9
21 GRN FTLD-TDP A 2 4 4 10
22 GRN FTLD-TDP A 4 2 1 7
23 GRN FTLD-TDP A 2 1 3 6
24 GRN FTLD-TDP A 2 0 1 3
25 GRN FTLD-TDP A 3 4 4 11
26 GRN FTLD-TDP A na 3 4 na
27 No mutation FTLD-TDP A 2 3 1 6
28 No mutation FTLD-TDP A 3 4 4 11
29 No mutation FTLD-TDP A 2 2 2 6
30 No mutation FTLD-TDP A 1 1 1 3
31 No mutation FTLD-TDP B 4 4 4 12
32 No mutation FTLD-TDP B 0 3 4 7
33 No mutation FTLD-TDP B 3 0 1 4
34 No mutation FTLD-TDP B 2 1 1 4
35 No mutation FTLD-TDP B 3 2 4 9
36 No mutation FTLD-TDP B 4 1 1 6
37 No mutation FTLD-TDP B 2 2 2 6
Table 3 Summated scores for TDP-43 pathology ratings
in Frontal and Temporal cortex, and Dentate Gyrus, as
well as total score across all 3 regions, for patients with
FTD (cases #1-8) or FTD +MND (cases#9-13) associated
with C9ORF72 expansions, and for patients with FTLD
due to GRN mutation (case#15-26) or not associated with
any known mutation (cases#27-40) (Continued)
38 No mutation FTLD-TDP B 1 0 1 2
39 No mutation FTLD-TDP B 1 2 3 6
40 No mutation FTLD-TDP B 3 3 3 9
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no significant correlations between the severity of TDP-43
pathology and either age at onset of disease, or duration of
illness, for either cortical, hippocampal or total scores. Nei-
ther was there any correlation between TDP-43 scores and
clinical phenotype (ie FTD versus FTD +MND).
Comparisons of TDP-43 severity scores according to
possession of at least one copy of APOE ε4 allele were
performed on 36/39 FTLD cases (for whom DNA was
available for genotyping), irrespective of the presence or
absence of mutation. No significant differences in the se-
verity of TDP-43 pathology scores were seen between
FTLD cases with APOE ε4 allele and FTLD cases with-
out APOE ε4 allele for either frontal cortex (p = 0.187),
temporal cortex (p = 0.293) or dentate gyrus of hippo-
campus (p = 0.171), or as total TDP-43 severity score
(p = 0.261). Similarly, comparisons of TDP-43 severity
scores according to heterozygosity (TC) or homozygosity
(TT) for major allele in TMEM106B were performed on
24/39 FTLD cases (where these data were available), irre-
spective of the presence or absence of mutation. No sig-
nificant differences in the severity of TDP-43 pathology
scores between FTLD cases with TC and TT geno-
types were seen for either frontal cortex (p = 0.301), tem-
poral cortex (p = 0.592) or dentate gyrus of hippocampus
(p = 0.768), or as total TDP-43 severity score (p = 0.519).
Discussion
There are two major outcomes from this study. Firstly,
that in cases of FTLD or MND bearing expansions in
C9ORF72, neither the topographical distribution, nor the
relative severity, of DPR differs between cases of FTD
alone, FTD +MND or MND alone. Secondly, neither
the morphological appearance, nor relative severity, of
TDP-43 immunoreactive changes differ in cases of
FTLD bearing an expansion in C9ORF72 from that in
non-expansion bearing cases of FTLD (ie sporadic forms
of FTLD), or from cases of FTLD bearing mutations
in GRN. These findings support the observations of
Mackenzie and colleagues [24] who likewise noted no
differences in either DPR or TDP-43 pathology between
expansion bearing cases of FTD alone, FTD +MND or
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relevance of DPR pathology in determining clinical
phenotype, and the role of the expansion per se in
causing FTLD or MND.
Expansions in C9ORF72 have been postulated to in-
voke disease by 3, mutually non-exclusive, mechanisms:
firstly involving a loss of C9orf72 protein through hap-
loinsufficiency [6], secondly by RNA toxicity through se-
questration of RNA species by the expanded sequences
[6,21], and thirdly through cytotoxicity from formation
and accumulation of DPR [18-20,22,23]. While this
latter suggestion is attractive, and has parallels with
other aggregating brain proteins such as tau, TDP-43,
α-synuclein, there is strong evidence that argues against
such an effect.
Firstly, in both the present, and in other studies [24],
the distribution of DPR, as evidenced by poly-GA immu-
nostaining, does not parallel that of neurodegeneration
(ie the TDP-43 proteinopathy) in either FTLD or MND.
Indeed, in both disorders the greatest severity of DPR
lies in brain regions such as the granule cell layer of the
cerebellum, the hippocampal dentate gyrus and CA4
pyramidal cells, and the parietal and occipital cortex,
with similar observations being recorded for poly-GP
and poly-GR antibodies [17]. Such affected regions of
the brain have hitherto not been considered to be in-
volved in the (TDP-43) pathological process, and are
brain regions which do not show obvious clinical reper-
cussions, which might be anticipated if the DPR were
principal in driving a neurodegenerative process, al-
though there have been reports of cerebellar atrophy in
expansion bearers [46,47].
Secondly, it is hard to conceive how a seemingly iden-
tical topographical pattern of DPR pathology could
determine, or even predispose towards, such diverse
clinical phenotypes as FTD or MND. To explain such an
apparent paradox, Mackenzie et al. 2013 [24] invoked the
argument that the visible DPR protein aggregates con-
ferred a neuroprotective effect in functionally preserved
brain regions with high DPR loads, such as cerebellum,
hippocampus and occipital cortex, through sequestration
of soluble toxic species. In the present study, we were
unable to show any significant differences in DPR load
between any of the neocortical regions investigated,
these being as equally high in functionally disturbed
areas such as frontal, temporal and motor cortex, as
those in apparently functionally normal regions such as
parietal and occipital cortex. It is therefore difficult to
reconcile such observations with any putative neuro-
protective effect, since if this were indeed the case then
it might be anticipated that visible DPR should be
lower in cortical regions, such as frontal and temporal
cortex, showing functional change and neurodegenera-
tion, in which any putative neurotoxic effects of soluble(oligomeric) precursors had not been so restricted. None-
theless, there does appear to be some clinical distinctions
between expansion bearers and non-bearers in both FTLD
and MND, in as much as expansion bearers in both condi-
tions are more likely to display psychosis [13,48,49]. Con-
cerning the present cases, there was no difference between
the level of DPR pathology in those cases presenting with a
florid psychosis compared to those where psychosis was
not apparent (data not shown), suggesting that the pres-
ence and/or extent of DPR pathology is neither a deter-
minant, nor a modulator, of psychosis.
The second observation from this study indicates that
as far as the TDP-43 proteinopathy is concerned, there
are again no distinctions in pathology between expan-
sion bearers and non-bearers of the expansion, either
overall or more specifically in respect of FTLD-TDP type
A or type B histologies. This also supports observations
by Mackenzie et al. [24] and further calls into question
the role of the expansion per se. Although, there is no a
priori reason to suspect that patients with an expansion
in C9ORF72 should ‘naturally’ carry a higher burden of
TDP-43 pathology than non-expansion carriers, it is none-
theless important to observe that such differences do in-
deed not exist. Moreover, if the expansion were directly
driving a TDP-43 proteinopathy, it is hard to reconcile this
with observations of different TDP-43 histologies. FTLD-
TDP Type B (involving a preponderance of neuronal
cytoplasmic inclusions) is the most common TDP-43
histological subtype associated with the expansion [12,24],
though a significant number of cases display type A hist-
ology [17], and rare cases with type C histology have been
described [12]. How such diverse histological patterns
could stem from a common genetic root is puzzling.
An alternative explanation of the role of C9ORF72
could be that the expansion acts as a risk factor for
FTLD and MND, though does not drive the (TDP-43)
pathological process directly, acting more as a ‘gate-
keeper’ to disease, rendering the brain susceptible to the
‘development’ of all sporadic forms of FTLD-TDP, and
sporadic forms of MND associated with TDP-43. Such a
scenario could accommodate the present observations of
the different histological types of TDP-43 proteinopathy
being associated with disease, and the relative propor-
tions with which they occur, and with findings that the
extent of TDP-43 pathology is the same in expansion
and non-expansion bearers both in terms of either type
A or type B histologies.
There is other evidence in support of this latter line of
argument. Firstly, although rare, pathologies other than
FTLD or MND, such as corticobasal degeneration [13,17],
Alzheimer’s disease ([50-52], but see [44]), Parkinson’s dis-
ease [53] and Huntington disease-like conditions [9], have
been associated with expansions in C9ORF72. Indeed,
there has been one Belgian case with C9ORF72 expansion
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ology, but shows FTLD-UPS pathology [7]. Secondly, there
appears to be no link between expansion size and TDP-43
histological type [17], or clinical phenotype [9]. Thirdly,
there appears to be a higher than expected coincidence of
repeat expansions in individuals carrying other genetic var-
iants involving mutations in GRN with C9ORF72 [54,55]
or MAPT with C9ORF72 [54-57] (so called oligogenic in-
heritance), suggesting that another ‘hit’ may be necessary
for clinical disease, yet in these dual mutation cases, apart
from the DPR changes, either a TDP-43 proteinopathy, or
tauopathy, typical of the accompanying (GRN or MAPT)
mutation prevails.
The correlation between age at onset and severity of
DPR pathology, unrelated to disease duration, is interest-
ing though the reason for this is unclear. It is possible
that there is a more severe ‘expression’ of the expansion
in younger individuals leading to a greater level of pro-
duction and accumulation of DPR, or that the dipeptides
aggregate more efficiently into NCI perhaps due to vari-
ations in length of DPR monomers formed as a result of
differences in translation efficiency with age during RAN
translation.
TMEM106B genotype (ie homozygosity for the minor
allele) has been claimed to be a genetic modifier of
FTLD in both GRN and C9ORF72 mutation carriers
[25,26,28,29], and to protect C9ORF72 carriers from FTD
[25,28,29]. Indeed, van Blitterwijk et al. [28] reported that
homozygous carriers of the minor protective TMEM106B
allele with FTLD-TDP type A histology appeared to have a
lower TDP-43 burden than homozygous carriers of the
major allele. Therefore, we investigated whether variations
at this locus might influence both the distribution and se-
verity of both DPR and TDP-43 pathologies in FTLD
cases associated with either C9ORF72 expansions or
GRN mutations. Unfortunately, no homozygous bearers
of TMEM106B minor allele were available in the present
study for either mutation, but we did not find any differ-
ences in DPR and TDP-43 pathology between hetero-
zygotes and those homozygous for the major allele
suggesting that heterozygosity, at least, does not confer a
‘partial’ protection in either C9ORF72 or GRN mutation
carriers. Similarly, although possession of at least one copy
of APOE ε4 allele has been (variably) claimed to increase
risk of FTLD [30-33], we found no significant differences
in extent of either DPR or TDP proteinopathy between ε4
allele bearers and non-bearers, implying that any putative
risk associated with ε4 allele does not operate through fa-
cilitating the pathological changes of FTLD.
How the expansion might act in a ‘gatekeeper’ role is
not clear. Much attention has been levied towards a de-
termination of the nature and effect of DPR in vivo, and
in vitro, as well as the role RNA foci might play in caus-
ing the disease. However, there is evidence of C9orf72haploinsufficiency in expansion carriers [6], though given
the paucity of knowledge surrounding the role and func-
tion of C9orf72, it is difficult to ascribe precise meaning
to such a putative loss of protein. A haploinsufficiency
state might impair vital ‘protective’ brain functions. Al-
ternatively, the formation of toxic RNA foci could like-
wise render cells vulnerable [6,21,23,58], though against
this are observations that such a process, like DPR for-
mation, is disseminated widely throughout the brain, and
not solely confined to those neuronal populations vulner-
able to TDP-43 proteinopathy. Present knowledge sug-
gests C9orf72 belongs to the differentially expressed in
normal and neoplastic (DENN)-like family of proteins,
these being GDP/GTP exchange factors which lead to ac-
tivation of Rab-GTPases and maintenance of vesicular
trafficking [59]. In this regard, it is interesting that the
most recent GWAS for FTLD has highlighted variations
in RAB38 as a risk factor for bvFTD [60]. RAB38 has been
suggested to mediate protein trafficking to lysosomal-
related organelles [61,62] and maturation of phagosomes
[63], and impairment in these processes might elicit cargo
accumulation in early endosomes, with downstream ef-
fects on recycling/degradative pathways [61]. Indeed, an
association with lysosomal processes in FTLD has previ-
ously been suggested by two studies on GRN [64] and
TMEM106B [65]. Considering that endolysosomal homeo-
stasis is essential for the health of neurons, functional links
between RAB38, TMEM106B, PGRN and FTLD imply dis-
turbances in C9orf72 may trigger or promote autophago-
somal/lysosomal dysfunctions, thereby playing a key role in
the onset and/or progression of the disease.
Nonetheless, if such a ‘gatekeeper role’ is true, then
the almost complete penetrance of the mutation needs
to be explained. In this respect the expansion might be
viewed as providing an ‘open door’ to disease, but with-
out actually causing disease directly, and in this regard
the DPR pathology may be a ‘red herring’ without patho-
genetic consequence. Clearly, until we know more about
the normal function of C9orf72 protein, what cells it is
present in, and where in the cell it is located, all is mere
speculation. The concept of the expansion being a risk
factor for disease, rather than a cause, is tempting since
it would neatly accommodate the observed diversity of
clinical and histological subtypes associated with the ex-
pansion. However, were the expansion to act as a risk
factor, it appears to act (almost) selectively for FTLD
and MND since expansions are only infrequently, and
then maybe only coincidentally, seen in more common
disorders such as Alzheimer’s and Parkinson’s disease
[50-53]. Therefore, while it is clear that expansions in
C9ORF72 are not without ‘pathological expression’, what
DPR might translate into in clinical terms is not clear,
and whether these structures confer anything beyond
diagnostic utility still remains to be demonstrated.
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